18 January 2024
18 January 2024
The decision invalidates all claims of patent infringement, which has been central in litigation of breast cancer drug Enhertu.
Speaking at Davos, WHO chief Dr. Ghebreyesus said learning lessons from the Covid-19 pandemic is a priority in fighting Disease X.
The Switzerland based company plans to use the Series B money to fund clinical trials for its three pipeline candidates.
Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.
The board of both companies have granted unanimous approval for the merger.
The investment will accelerate the clinical development of a fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical therapeutic.
Windtree is entitled to receive $138.1m in milestone payments.
The British health insurance and coverage provider is well-placed to invest in new technology due to its payment structure.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
